PROJECT IN DETAILS

The number of chronic diseases caused by adverse immune reactions is continuously increasing.
To date, this group of diseases affects over 10% of the global population. In addition to the high burden on the patients (chronicity, organ failure, early death, reduced quality of life), this results in great direct and indirect costs for society (EU: >100 billion €/year direct health care costs).

While symptoms can be treated, there is currently no cure.
Therapies have limited efficacy. Many times, the disturbed immune balance cannot be restored sustainably.
The consortium behind the “geneTIGA” project is addressing this problem using the example of IgA nephropathy (IgAN), the most common immunological kidney disease (glomerulonephritis), which is also one of the most common causes of kidney failure.

Start

1 July 2022

Duration

48 Months

Funding

€ 5.7 Mio

Team

11 Partners